Hypertriglyceridemia

Revision as of 12:50, 26 September 2011 by C Michael Gibson (talk | contribs)
Jump to navigation Jump to search

Template:DiseaseDisorder infobox

WikiDoc Resources for Hypertriglyceridemia

Articles

Most recent articles on Hypertriglyceridemia

Most cited articles on Hypertriglyceridemia

Review articles on Hypertriglyceridemia

Articles on Hypertriglyceridemia in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Hypertriglyceridemia

Images of Hypertriglyceridemia

Photos of Hypertriglyceridemia

Podcasts & MP3s on Hypertriglyceridemia

Videos on Hypertriglyceridemia

Evidence Based Medicine

Cochrane Collaboration on Hypertriglyceridemia

Bandolier on Hypertriglyceridemia

TRIP on Hypertriglyceridemia

Clinical Trials

Ongoing Trials on Hypertriglyceridemia at Clinical Trials.gov

Trial results on Hypertriglyceridemia

Clinical Trials on Hypertriglyceridemia at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Hypertriglyceridemia

NICE Guidance on Hypertriglyceridemia

NHS PRODIGY Guidance

FDA on Hypertriglyceridemia

CDC on Hypertriglyceridemia

Books

Books on Hypertriglyceridemia

News

Hypertriglyceridemia in the news

Be alerted to news on Hypertriglyceridemia

News trends on Hypertriglyceridemia

Commentary

Blogs on Hypertriglyceridemia

Definitions

Definitions of Hypertriglyceridemia

Patient Resources / Community

Patient resources on Hypertriglyceridemia

Discussion groups on Hypertriglyceridemia

Patient Handouts on Hypertriglyceridemia

Directions to Hospitals Treating Hypertriglyceridemia

Risk calculators and risk factors for Hypertriglyceridemia

Healthcare Provider Resources

Symptoms of Hypertriglyceridemia

Causes & Risk Factors for Hypertriglyceridemia

Diagnostic studies for Hypertriglyceridemia

Treatment of Hypertriglyceridemia

Continuing Medical Education (CME)

CME Programs on Hypertriglyceridemia

International

Hypertriglyceridemia en Espanol

Hypertriglyceridemia en Francais

Business

Hypertriglyceridemia in the Marketplace

Patents on Hypertriglyceridemia

Experimental / Informatics

List of terms related to Hypertriglyceridemia

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Hypertriglyceridemia (or "Hypertriglyceridaemia") denotes high (hyper-) blood levels (-emia) of triglycerides, the most abundant fatty molecule in most organisms. It has been associated with atherosclerosis, even in the absence of hypercholesterolemia (high cholesterol levels). It can also lead to pancreatitis in excessive concentrations. Very high triglyceride levels may also interfere with blood tests; hyponatremia may be reported spuriously (pseudohyponatremia).

A related term is "Hyperglyceridemia" or "Hyperglyceridaemia", which refers to a high level of all glycerides, including monoglycerides, diglycerides and triglycerides.

Causes

Treatment

Treatment of hypertriglyceridemia is by restriction of carbohydrates and fat in the diet, as well as with niacin, fibrates and statins (three classes of drugs). Increased fish oil intake may substantially lower an individual's triglycerides.[1][2][3]

Clinical practice guidelines by the National Cholesterol Education Program (NCEP) suggests that pharmacotherapy be considered with triglycerides are over 200 mg/dl.[4] The guidelines state "the sum of LDL + VLDL cholesterol (termed non-HDL cholesterol [total cholesterol - HDL cholesterol]) as a secondary target of therapy in persons with high triglycerides (200 mg/dL). The goal for non-HDL cholesterol in persons with high serum triglycerides can be set at 30 mg/dL higher than that for LDL cholesterol (Table 9) on the premise that a VLDL cholesterol level 30 mg/dL is normal."[4]

Primary prevention

In the Helsinki Heart Study, a randomized controlled trial of asymptomatic men ages 40-55 without heart disease, 600 mg of gemfibrozil twice daily reduced cardiac endpoints at 5 years from 4.14% to 2.73%. This means that 54 patients must be treated for five years to prevent one cardiac event (number needed to treat is 54).[5]

Secondary prevention

In the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study (VA-HIT), a randomized controlled trial of men with known heart disease HDL cholesterol of 40 mg/dl or less , 600 mg of gemfibrozil twice daily reduced cardiac endpoints ( nonfatal myocardial infarction or death from coronary causes) at 5 years from 21.7% to 17.3%. This means that 23 patients must be treated for five years to prevent one cardiac event (number needed to treat is 23).[6]

References

  1. "Lipids Online Slides: hypertriglyceridemia, ICAM-1, fish oil, E-selectin".
  2. Terres W, Beil U, Reimann B, Tiede S, Bleifeld W (1991). "[Low-dose fish oil in primary hypertriglyceridemia. A randomized placebo-controlled study]". Zeitschrift für Kardiologie (in German). 80 (1): 20–4. PMID 2035283.
  3. "Fish oils in hypertriglyceridemia - Fish Oils Revisited Nutrition Research Newsletter - Find Articles".
  4. 4.0 4.1 "Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)". JAMA. 285 (19): 2486–97. 2001. PMID 11368702.
  5. Frick MH, Elo O, Haapa K; et al. (1987). "Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease". N. Engl. J. Med. 317 (20): 1237–45. PMID 3313041.
  6. Rubins HB, Robins SJ, Collins D; et al. (1999). "Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group". N. Engl. J. Med. 341 (6): 410–8. PMID 10438259.


Template:WikiDoc Sources